This review discusses evidence for use of the Nurofen® Duralast 200 mg ibuprofen dermal patch as a shortterm symptomatic treatment for musculoskeletal pain. Nurofen® Duralast is the first over-the-counter ibuprofen dermal patch in New Zealand to provide localised relief from pain and associated tenderness over a 24-hour period. This review is sponsored by an educational grant from Reckitt Benckiser.
Please login below to download this issue (PDF)